To unlock this feature and to subscribe to our weekly evidence emails, please create a FREE orthoEvidence account.

SIGNUP

Already Have an Account?

Loading...
Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Ace Report Cover

Titrated THC and CBD does not significantly improve spasticity compared to placebo over 4 weeks

Download
Share
Reprints
Cite This
About
+ Favorites
Share
Reprints
Cite This
About
+ Favorites
Ace Report Cover
January 2019

Titrated THC and CBD does not significantly improve spasticity compared to placebo over 4 weeks

Vol: 8| Issue: 1| Number:12| ISSN#: 2564-2537
Study Type:Therapy
OE Level Evidence:2
Journal Level of Evidence:N/A

Sativex and clinical-neurophysiological measures of spasticity in progressive multiple sclerosis

J Neurol. 2015 Nov;262(11):2520-7

Contributing Authors:
E Houdayer A Nuara L Straffi G Comi P Rossi LN Leocani I Schiavetti U Del Carro S Amadio V Martinelli C Vila MP Sormani

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here

Synopsis

34 patients with progressive multiple sclerosis were treated with titrated doses of Sativex (9-delta-tetrahydrocannabinol and cannabidiol oromucosal spray) or placebo in a randomly assigned order for 4 weeks each. The purpose of the study was to determine if of 9-delta-tetrahydrocannabinol and cannabidiol treatment significantly improves neurophysiological and clinical measures of spasticity, pain...

CME Image

Did you know that you’re eligible to earn 0.5 CME credits for reading this report!

LEARN MORE

Join the Conversation

Please Login or Join to leave comments.